Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Penicillin-binding proteins (PBPs) 1A, 1B, 3, and 4 are essential enzymes in Escherichia coli that catalyze the final stages of peptidoglycan biosynthesis, which is critical for maintaining the structural integrity and shape of the bacterial cell wall [1, 2, 5]. PBP1A (mrcA) and PBP1B (mrcB) are high-molecular-weight Class A bifunctional enzymes possessing both transglycosylase and transpeptidase activities; they are functionally redundant, but the presence of at least one is required for cell viability [3, 9]. PBP3 (ftsI) is a Class B transpeptidase specifically required for the formation of the division septum, and its inhibition leads to the arrest of cell division and the formation of long filaments [10, 12]. PBP4 (dacB) is a low-molecular-weight Class C enzyme with DD-carboxypeptidase and endopeptidase activities involved in the remodeling and maturation of the peptidoglycan layer [1, 9]. These proteins are the primary therapeutic targets for beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems, which act as suicide inhibitors by covalently binding to the active site serine [5, 8, 10]. Inhibition of these PBPs disrupts cell wall assembly, leading to osmotic instability, cell lysis, and bacterial death [4, 10].
Covalent inhibition of the transpeptidase domain by acting as a structural analog of the D-alanyl-D-alanine terminus of peptidoglycan precursors, thereby preventing cell wall cross-linking and leading to bacterial lysis [2, 5, 8, 10].
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Penicillin-binding proteins 1A, 1B, 3, and 4 (Escherichia coli) (PBPs (1A, 1B, 3, 4)).